文献速递心脑血管急症

CANTOS随机对照试验二次分析:卡那奴单抗治疗后C反应蛋白降低与心血管事件减少的关系

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
PubMed 文献 · Lancet · 2017-11-13
一句话结论CANTOS二次分析显示,卡那奴单抗治疗后hsCRP降至<2 mg/L者主要不良心血管事件风险降低25%,而≥2 mg/L者无显著获益。

CANTOS试验将10061例有心肌梗死病史的男性和女性随机分配至安慰剂或卡那奴单抗50 mg、150 mg、300 mg皮下注射每3个月一次。这项预设二次分析按治疗中hsCRP浓度评估卡那奴单抗对主要不良心血管事件、心血管死亡和全因死亡的影响,中位随访3.7年。结果显示,基线临床特征不能定义获益更大或更小的患者组;但分配至卡那奴单抗且达到hsCRP<2 mg/L者主要不良心血管事件减少25%(多变量校正HR=0.75,95%CI 0.66-0.85,p<0.0001),而hsCRP≥2 mg/L者无显著获益(HRadj=0.90,0.79-1.02,p=0.11)。达到hsCRP<2 mg/L者心血管死亡和全因死亡均降低31%,而≥2 mg/L者无显著降低。作者认为单次卡那奴单抗后hsCRP降低幅度可能提供简单临床方法识别最可能从持续治疗中获益最大的个体,并提示炎症降低越低越好。

要点

  • 分配至卡那奴单抗且治疗中hsCRP<2 mg/L者主要不良心血管事件减少25%(HRadj=0.75,95%CI 0.66-0.85,p<0.0001)。
  • 治疗中hsCRP≥2 mg/L者主要不良心血管事件无显著获益(HRadj=0.90,95%CI 0.79-1.02,p=0.11)。
  • 达到hsCRP<2 mg/L者心血管死亡(HRadj=0.69,95%CI 0.56-0.85,p=0.0004)和全因死亡(HRadj=0.69,95%CI 0.58-0.81,p<0.0001)均降低31%。
  • 基线临床特征不能定义卡那奴单抗治疗获益更大或更小的患者组。
  • 作者认为单次卡那奴单抗后hsCRP降低幅度可能识别最可能从持续治疗中获益最大的个体。

适用人群与场景

  • 有心肌梗死病史的男性和女性,来自CANTOS试验随机分配的10061例参与者。
  • 预设二次分析按治疗中hsCRP浓度评估,中位随访3.7年。

诊断标准与关键阈值

  • 治疗中hsCRP浓度界值:<2 mg/L vs ≥2 mg/L。

处置流程与药物剂量

  • 卡那奴单抗50 mg、150 mg或300 mg皮下注射,每3个月一次;对照为安慰剂。

研究设计与关键结果

  • 研究类型:CANTOS随机对照试验的预设二次分析;样本量10061例有心肌梗死病史的男性和女性;干预为卡那奴单抗50 mg、150 mg、300 mg皮下注射每3个月一次 vs 安慰剂;中位随访3.7年。
  • 主要终点:分配至卡那奴单抗且治疗中hsCRP<2 mg/L者主要不良心血管事件减少25%(多变量校正HR=0.75,95%CI 0.66-0.85,p<0.0001);hsCRP≥2 mg/L者无显著获益(HRadj=0.90,95%CI 0.79-1.02,p=0.11)。
  • 关键次要终点:达到hsCRP<2 mg/L者心血管死亡降低31%(HRadj=0.69,95%CI 0.56-0.85,p=0.0004),全因死亡降低31%(HRadj=0.69,95%CI 0.58-0.81,p<0.0001);hsCRP≥2 mg/L者这些终点无显著降低。
  • 预设次要心血管终点(额外包括因不稳定心绞痛住院需非计划血运重建)及基于hsCRP中位降低、hsCRP降低≥50%、hsCRP中位百分比降低、剂量特异性分析和因果推断方法的敏感性分析中,发现相似的差异效应。
  • 基线临床特征不能定义获益更大或更小的患者组。

证据类型、等级与局限

  • 证据类型:CANTOS随机对照试验的预设二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为单次卡那奴单抗后hsCRP降低幅度可能提供简单临床方法,识别最可能从持续治疗中获益最大的个体。
  • 作者认为这些数据进一步提示用卡那奴单抗降低炎症时越低越好。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Canakinumab, a monoclonal antibody targeting interleukin-1β, reduces inflammation and cardiovascular event rates with no effect on lipid concentrations. However, it is uncertain which patient groups benefit the most from treatment and whether reductions in the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) correlate with clinical benefits for individual patients.

METHODS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) used computer-generated codes to randomly allocate 10 061 men and women with a history of myocardial infarction to placebo or one of three doses of canakinumab (50 mg, 150 mg, or 300 mg) given subcutaneously once every 3 months. In a prespecified secondary analysis designed to address the relationship of hsCRP reduction to event reduction in CANTOS, we evaluated the effects of canakinumab on rates of major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality according to on-treatment concentrations of hsCRP. We used multivariable modelling to adjust for baseline factors associated with achieved hsCRP and multiple sensitivity analyses to address the magnitude of residual confounding. The median follow-up was 3·7 years. The trial is registered with ClinicalTrials.gov, number NCT01327846.

FINDINGS: Baseline clinical characteristics did not define patient groups with greater or lesser cardiovascular benefits when treated with canakinumab. However, trial participants allocated to canakinumab who achieved hsCRP concentrations less than 2 mg/L had a 25% reduction in major adverse cardiovascular events (multivariable adjusted hazard ratio [HRadj]=0·75, 95% CI 0·66-0·85, p<0·0001), whereas no significant benefit was observed among those with on-treatment hsCRP concentrations of 2 mg/L or above (HRadj=0·90, 0·79-1·02, p=0·11). For those treated with canakinumab who achieved on-treatment hsCRP concentrations less than 2 mg/L, cardiovascular mortality (HRadj=0·69, 95% CI 0·56-0·85, p=0·0004) and all-cause mortality (HRadj=0·69, 0·58-0·81, p<0·0001) were both reduced by 31%, whereas no significant reduction in these endpoints was observed among those treated with canakinumab who achieved hsCRP concentrations of 2 mg/L or above. Similar differential effects were found in analyses of the trial prespecified secondary cardiovascular endpoint (which additionally included hospitalisation for unstable angina requiring unplanned revascularisation) and in sensitivity analyses alternatively based on median reductions in hsCRP, on 50% or greater reductions in hsCRP, on the median percent reduction in hsCRP, in dose-specific analyses, and in analyses using a causal inference approach to estimate the effect of treatment among individuals who would achieve a targeted hsCRP concentration.

INTERPRETATION: The magnitude of hsCRP reduction following a single dose of canakinumab might provide a simple clinical method to identify individuals most likely to accrue the largest benefit from continued treatment. These data further suggest that lower is better for inflammation reduction with canakinumab.

FUNDING: Novartis Pharmaceuticals.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Ridker PM, MacFadyen JG, Everett BM, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2017. PMID: 29146124. doi:10.1016/S0140-6736(17)32814-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。